Sare Hosseini - Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Jamshidkhan Chamani - Department of Biology, Faculty of Sciences, Islamic Azad University-Mashhad Branch, Mashhad, Iran.
Hamidreza Rahimi - Department of Modern Sciences & Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Navid Azmoodeh - Department of Biology, Faculty of Sciences, Islamic Azad University-Mashhad Branch, Mashhad, Iran.
Faezeh Ghasemi - Department of Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Porya Hassan Abadi - School of Medicine, University of Birmingham, Birmingham, UK.

Background: The incidence of esophageal squamous cell carcinoma (ESCC) is increasing, causing catastrophic health burdens on communities. Curcumin has shown promise as a therapeutic agent in the treatment of colon, colorectal, pancreatic, and esophageal cancers but it has very poor bioavailability. The application of nano-carriers as drug delivery systems increases curcuminchr('۳۹')s bioavailability. Cyclin D۱ is overexpressed in ESCC and curcumin may change its expression. Methods: In this study, the effect of SinaCurcumin®, a novel nano-micelle product containing ۸۰ mg curcumin, on the growth of KYSE-۳۰ cells and expression of cyclin D۱, was investigated. Paclitaxel and Carboplatin served as reference drugs. Results: Nano-curcumin increased cell cytotoxicity, decreased IC۵۰, and down-regulated of cyclin D۱. However, treatment of cells with nano-curcumin might result in multidrug resistance. Conclusions: Nano-curcumin suppressed proliferation of KYSE-۳۰ cells and expression of cyclin D۱ although its use in combination with other chemotherapeutic agents requires further testing.

Curcumin, Cyclin D۱ gene, Drug resistance, KYSE-۳۰ cells, Nano-Micelle